Division of Vascular Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Vascular Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
J Endovasc Ther. 2024 Oct;31(5):831-839. doi: 10.1177/15266028221147457. Epub 2023 Jan 7.
Endovascular revascularization is the preferred treatment to improve perfusion of the lower extremity in patients with chronic limb-threatening ischemia (CLTI). Patients with CLTI often present with stenotic-occlusive lesions involving the infrapopliteal arteries. Although the frequency of treating infrapopliteal lesions is increasing, the reintervention rates remain high. This study aimed to determine the outcomes and patency of infrapopliteal endovascular reinterventions.
This retrospective, multicenter cohort study of 3 Dutch hospitals included patients who underwent an endovascular infrapopliteal reintervention in 2015 up to 2021 after a primary infrapopliteal intervention for CLTI. The outcome measures after the reintervention procedures included technical success rate, the mortality rate and complication rate (any deviation from the normal postinterventional course) at 30 days, overall survival, amputation-free survival (AFS), freedom from major amputation, major adverse limb event (MALE), and recurrent reinterventions (a reintervention following the infrapopliteal reintervention). Cox proportional hazard models were used to determine risk factors for AFS and freedom from major amputation or recurrent reintervention.
Eighty-one patients with CLTI were included. A total of 87 limbs underwent an infrapopliteal reintervention in which 122 lesions were treated. Technical success was achieved in 99 lesions (81%). The 30-day mortality rate was 1%, and the complication rate was 13%. Overall survival and AFS at 1 year were 69% (95% confidence interval [CI], 55%-79%) and 54% (95% CI, 37%-67%), respectively, and those at 2.5 years were 45% (95% CI, 33%-56%) and 21% (95% CI, 11%-33%), respectively. Freedom from major amputation, MALE, and recurrent reinterventions at 1 year and 2.5 years were 59% (95% CI, 46%-70%) and 41% (95% CI, 25%-56%); 54% (95% CI, 41%-65%) and 36% (95% CI, 21%-51%); and 68% (95% CI, 55%-78%) and 51% (95% CI, 33%-66%), respectively. A Global Limb Anatomic Staging System score of III showed an increased hazard ratio of 2.559 (95% CI, 1.078-6.072; p=0.033) for freedom of major amputation or recurrent reintervention.
The results of this study indicate that endovascular infrapopliteal reinterventions can be performed with acceptable 30-day mortality and complication rates. However, outcomes and patency were moderate to poor, with low AFS, high rates of major amputations, and recurrent reinterventions.
This multicenter retrospective study evaluating outcome and patency of endovascular infrapopliteal reinterventions for CLTI, shows that endovascular infrapopliteal reinterventions can be performed with acceptable 30-day mortality and complication rates. However, the short- and mid-term outcomes of the infrapopliteal reinterventions were moderate to poor, with low rates of AFS and a high need for recurrent reinterventions. While the frequency of performing infrapopliteal reinterventions is increasing with additional growing complexity of the disease, alternative treatment options such as venous bypass grafting or deep venous arterialization may be considered and should be studied in randomized controlled trials.
血管腔内血运重建是改善慢性肢体严重缺血(CLTI)患者下肢灌注的首选治疗方法。CLTI 患者常表现为累及腘动脉以下的狭窄-闭塞性病变。尽管治疗腘动脉以下病变的频率在增加,但再干预率仍然很高。本研究旨在确定腘动脉以下血管腔内再干预的结果和通畅率。
这是一项回顾性的、多中心队列研究,纳入了 2015 年至 2021 年期间在荷兰的 3 家医院接受过腘动脉以下血管腔内再干预的 CLTI 患者。再干预后 30 天的评估指标包括技术成功率、死亡率和并发症率(任何与正常术后过程的偏差)、总生存率、免于截肢生存率(AFS)、免于大截肢生存率、重大不良肢体事件(MALE)和再复发干预(腘动脉以下再干预后的再次干预)。使用 Cox 比例风险模型确定 AFS 和免于大截肢或再复发干预的风险因素。
共纳入 81 例 CLTI 患者,87 条肢体接受了腘动脉以下再干预,其中 122 处病变接受了治疗。99 处病变(81%)达到了技术成功。30 天死亡率为 1%,并发症率为 13%。1 年时的总生存率和 AFS 分别为 69%(95%置信区间,55%-79%)和 54%(95%置信区间,37%-67%),2.5 年时分别为 45%(95%置信区间,33%-56%)和 21%(95%置信区间,11%-33%)。1 年和 2.5 年时的免于大截肢、MALE 和再复发干预的比例分别为 59%(95%置信区间,46%-70%)和 41%(95%置信区间,25%-56%)、54%(95%置信区间,41%-65%)和 36%(95%置信区间,21%-51%)和 68%(95%置信区间,55%-78%)和 51%(95%置信区间,33%-66%)。Global Limb Anatomic Staging System 评分 III 显示,大截肢或再复发干预的自由风险比为 2.559(95%置信区间,1.078-6.072;p=0.033)。
本研究结果表明,腘动脉以下血管腔内再干预可在可接受的 30 天死亡率和并发症率下进行。然而,结果和通畅率为中等至较差,AFS 较低,大截肢率较高,需要再次干预。
这项多中心回顾性研究评估了 CLTI 腘动脉以下血管腔内再干预的结果和通畅率,表明腘动脉以下血管腔内再干预可在可接受的 30 天死亡率和并发症率下进行。然而,腘动脉以下再干预的短期和中期结果为中等至较差,AFS 率较低,需要再次干预的频率较高。尽管治疗腘动脉以下病变的频率随着疾病的进一步发展而增加,但可以考虑其他治疗方法,如静脉旁路移植或深静脉动脉化,并应在随机对照试验中进行研究。